Abbvie and Voyager Are Collaborating on Antibody-based Gene Therapies for Alzheimer’s

Abbvie and Voyager Are Collaborating on Antibody-based Gene Therapies for Alzheimer’s
AbbVie and Voyager Therapeutics are teaming up to develop antibody-based gene therapies for Alzheimer’s and other neurodegenerative disorders. The collaboration includes gene therapies against the harmful tau protein in the brains of Alzheimer’s patients. An antibody is a protein the immune system generates to fight harmful substances. Companies can produce antibodies in a laboratory as treatments

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *